News

NovaRock Biotherapeutics Announces Exclusive LICENSE AGREEMENT and STRATEGIC PARTNERSHIP with Flame BioSciences

NovaRock granted Flame Biosciences exclusive license (excluding China, Hong Kong, Macau, and Taiwan) to co-develop, manufacture, and commercialize NBL-015, a […]

NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-015

Ewing, NJ, May 24, 2021– NovaRock Biotherapeutics Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared […]

NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Gastric Cancer

Ewing, NJ, April 7, 2021 – NovaRock Biotherapeutics Ltd announced today that their investigational new drug, NBL-015, a Claudin18.2 eADCC […]

NovaRock Biotherapeutics Announces Two E-Posters to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2021

Ewing, NJ, March 30, 2021 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]

NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases

Ewing, NJ, January 6, 2021 – NovaRock Biotherapeutics Ltd, announced today that the U.S. Food and Drug Administration (FDA) has […]

NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Pancreatic Cancer

Ewing, NJ, December 3, 2020 – NovaRock Biotherapeutics Ltd, announced today that their investigational new drug, NBL-015, has been granted […]